FDA panel to decide fate of diabetes drug Avandia
The fate of the diabetes drug Avandia will likely be decided soon by an expert panel that has spent the past two days reviewing evidence that linked the drug to serious cardiovascular events and whether its developer and manufacturer, GlaxoSmithKline (GSK), influenced the results of a study asserting the safety of Avandia.